APG-2575 Clinical Trials

5 actively recruiting trials across 2 locations

Pipeline

Early 1: 1Phase 1: 1Phase 2: 1Phase 1/2: 2

Top Sponsors

Ascentage Pharma Group Inc.5

Indications

Cancer4
SLE1
Non-Hodgkins Lymphoma1
T-Prolymphocytic Leukemia1
Lupus1

Other3 trials

A Study of APG-2575 in Patients With Mild-to-moderate Systemic Lupus Erythematosus.

Phase 1/2

APG-115 Alone or in Combination With APG-2575 in Children With Recurrent or Refractory Neuroblastoma or Solid Tumors

Phase 1

Study of APG2575 Single Agent and Combination Therapy in Patients With Relapsed/Refractory CLL/SLL

Phase 1/2

Jacksonville, Florida1 trial

APG-2575 Study of Safety, Tolerability ,PK/PD in Patients With Hematologic Malignancies

Mayo Clinic

Early 1

Houston, Texas1 trial

A Study Evaluating APG-115 as a Single Agent or in Combination With APG-2575 in Subjects With R/R T-PLL and NHL

MD Anderson

Phase 2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.